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Abstract
The increase in the number of methicillin-resistant Staphylococcus aureus (MRSA) infections in children has prompted paediatricians to
broaden th empirical treatment of common community-onset (CO) infections in children in several countries. Most European countries
have reported low rates of CO-MRSA infection, but limited data on paediatric CO-MRSA infections are available. A prospective study
was conducted from January 2002 to December 2004 in Brussels. CO-MRSA was defined as MRSA first detected by culture within 48 h
of admission or in outpatients. Clinical and epidemiological data were recorded. CO-MRSA strains were genotyped by pulsed-field gel
electrophoresis and multilocus sequence typing. Staphylococcal chromosomal cassette mec, toxin (Panton–Valentin leukocidin (PVL), toxic
shock syndrome toxin 1, and Eta/b), enterotoxin and antibiotic resistance genes were detected by PCR. The antibiotic resistance pheno-
type was determined by disk diffusion. S. aureus was isolated in 1681 children. Among these, 107 harboured MRSA. Fifty-one children
were colonized or infected by CO-MRSA, 20% of whom had no healthcare exposure. Twelve infants <3 months old and five cystic fibro-
sis patients were colonized. None of the 22 infected patients (59% with acute otitis media and 36% with skin and soft tissue infections
(SSTIs)) required hospitalization. Two-thirds of them failed to respond to empirical antibiotic therapy. The 37 characterized CO-MRSA
strains were genetically diverse. Most of them had healthcare-associated genotypes. Only six strains were PVL-positive, all of which were
ciprofloxacin-susceptible and more common in children with SSTIs (p 0.001). CO-MRSA remains uncommon in our paediatric population.
So far, there is no need to modify the empirical treatment of common S. aureus infections. Monitoring of MRSA rates in S. aureus CO
infections remains mandatory, and further investigation is warranted to establish the source of colonization in young infants.
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Community-acquired (CA) methicillin-resistant Staphylococcus
aureus (MRSA) infections in children are now encountered
frequently in the USA, especially in particular regions, such
as Texas, but also in some European countries such as
Greece [1,2]. In Europe, studies have been conducted in
several countries to evaluate the occurrence of infections
caused by CA-MRSA, using different definitions. Indeed, the
distinction between CA-MRSA and hospital-acquired (HA)-
MRSA has been based on epidemiological and molecular
characteristics and antibiotic susceptibility profiles [3]. In
western Europe, CA-MRSA has been isolated from infec-
tions in paediatric patients, but it remains infrequent so far
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[4–6]. Notably, several reports of CA-MRSA infection in
children and adults have come from the Nordic countries,
which have very low rates of HA-MRSA [7]. In these coun-
tries, importation of MRSA into the community from
abroad has been well documented [8]. CA-MRSA-infected
patients lack the risk factors associated with HA-MRSA
infection; that is, they have no underlying chronic disease
and no direct or indirect contact with hospitals [9]. CA-
MRSA strains are usually susceptible to non-b-lactam antibi-
otics, often carry the Panton–Valentine leukocidin (PVL)
toxin genes, and may belong to specific clonal lineages,
although some CA-MRSA strains are resistant to macrolides
or fluoroquinolones, some lack PVL, and some share a
common ancestor with HA-MRSA strains [3]. Moreover,
CA-MRSA strains were initially found to carry particular
types (IV and V) of the mobile genetic element carrying the
methicillin resistance determinant staphylococcal chromo-
somal cassette mec (SCCmec) [10]. Today, both HA-MRSA
and CA-MRSA strains circulate in the community, and CA-
MRSA strains have been described in nosocomial infections
and outbreaks, thereby gradually obscuring this distinction
[3,7]. In contrast to the US situation, where a few CA-
MRSA genotypes (the largely predominant USA300-ST8-
SCCmec IV, ST30-IV, ST1-IV, and ST59-V) cause the vast
majority of infections [11], with an overrepresentation of
skin and soft tissue infections (SSTIs), more diverse geno-
types are described in European countries [12–14].
In Belgium, the proportions of MRSA clinical isolates
reported by the hospital surveillance system were 29% in
2003 and 25% in 2008 [15]. As in other European countries
[16,17], new clones have emerged to replace the widespread
multidrug-resistant type ST247-I ‘Iberian’ clone, and the pre-
dominant clones belong now to five major sequence types
(STs), ST45-IV, ST8-IV (comprising two predominant distinct
pulsed-field gel electrophoresis (PFGE) types), ST5-IV, ST5-II,
and ST22-IV [18]. Limited information is available regarding
MRSA acquired outside the hospital in the paediatric popula-
tion in Belgium. CA-MRSA strains were rarely reported to
the Belgian reference laboratory, but analysis of the 16 PVL-
positive strains sent during 2002–2004 showed that these
PVL-positive MRSA strains belonged to five genotypes: ST80-
IV, the predominant European CA-MRSA clone, which was
the most frequent, ST8-IV, ST30-IV, ST153-IV, and PFGE
ST88-IV. These clones were distinct from the clones recov-
ered in hospital infections [13]. We conducted the present
study to determine the proportion of community-onset
(CO)-MRSA among S. aureus and to analyse their genetic
diversity and PVL prevalence. We also describe the clinical
characteristics and exposure to risk factors in children colo-
nized or infected with CO-MRSA.
Materials and Methods
Study setting and patient population
We conducted a prospective cohort study from 1 January
2002 to 31 December 2004 in Hoˆpital Universitaire des En-
fants Reine Fabiola (HUDERF), a university paediatric hospital
and teaching centre with 169 paediatric beds, 11 000 annual
admissions, and 100 000 outpatients and emergency room
visits, of which approximately 50% are for primary care. Chil-
dren cared for in our hospital have usually no direct or indi-
rect contact with adult patients within the hospital. Children
admitted to the intensive-care unit, haemato-oncology unit,
referred from other hospitals or coming from foreign coun-
tries were systematically screened for MRSA by culture of
nasal and inguinal skin swabs. The study protocol was
approved by the ULB-HUDERF ethical review committee.
Oral consent was obtained from the parents.
Data collection and epidemiological definitions
All MRSA cases were notified daily to the paediatric infec-
tious disease and infection control team by the hospital mi-
crobiologists. The total numbers of MRSA and S. aureus
isolates from inpatients and outpatients were also registered
during the study period.
CO-MRSA was defined as MRSA first detected by culture
from inpatients within 48 h of admission or in outpatients.
MRSA isolates detected after 48 h of hospital stay were con-
sidered to have been nosocomially acquired (HA-MRSA).
Patients with CO-MRSA recovered from either a clinical or
a screening sample were included in the study. Patients were
only included once, with one sample per patient being taken
during the study period. Patients transferred from another
hospital, children with surgical wound infection and children
previously known to be infected or colonized with MRSA
were excluded. MRSA isolates were defined as colonizers if
they were recovered only from screening swabs, nasopha-
ryngeal aspirates, or throat swabs, in the absence of a posi-
tive clinical site.
A CA-MRSA isolate was defined as a CO-MRSA isolate in
children with no exposure to healthcare-associated risk fac-
tors, such as previous hospitalization, underlying chronic
condition, and close contact with a sibling or care-giver with
an increased risk of HA-MRSA carriage (stay or work in a
hospital or nursing home).
Demographic and clinical data were recorded prospec-
tively with a predefined questionnaire administered by a pae-
diatrician or the infection control nurse directly to the
parents. Missing data were completed by retrospective chart
review and telephone interviews of the parents. Collected
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data included age, sex, ethnic origin, place of residence, tra-
vel history in the previous year, main primary clinical diagno-
sis, date of first MRSA-positive sample, type of sample,
hospitalization, history of hospitalization in the previous
12 months, comorbidities, antibiotic use in the previous
6 months (including topical formulations), day-care atten-
dance, siblings (number and medical history), parent occupa-
tion and past medical history (including hospital contacts),
and family or household members staying or working in
healthcare institutions (including nursing homes) with a his-
tory of hospital contact (chronic disease or stay in the previ-
ous year) or self-reported MRSA carriage or infection at the
time of contact.
Detection and characterization of MRSA strains
S. aureus isolates were identified by colony morphology on
Columbia blood agar plates (Becton Dickinson, Sparks, MD,
USA) and coagulase tube tests on human plasma. Oxacillin
resistance was determined with the AST P549 card from the
Vitek II system (bioMe´rieux, Marcy l’Etoile, France). CO-
MRSA strains were sent to the National Reference Labora-
tory for Staphylococci. Identification of MRSA was confirmed
by a triplex PCR, amplifying fragments of the mecA, nuc and
16 rRNA genes [19].
Antibiotic resistance was determined by disk diffusion (Ro-
sco Neo-Sensitabs, Taastrup, Denmark), with the CLSI
breakpoints for penicillin, oxacillin, erythromycin, clindamy-
cin, gentamicin, kanamycin, tobramycin, ciprofloxacin, co-
trimoxazole, rifampicin, linezolid, tetracycline, and minocyclin
[20]. Antibiotic resistance was also determined by disk diffu-
sion for fusidic acid and mupirocin, according to the criteria
of the Committee for Antimicrobial Testing of the French
Society of Microbiology and the British Society for Antimi-
crobial Chemotherapy, respectively [21,22].
Molecular typing of the CO-MRSA strains
The following resistance genes were detected by PCR:
tetK, tetM, ant(4¢), aph(3¢), aac(6¢), aph(2¢¢), ermA, and ermC
[18]. Virulence genes encoding 16 enterotoxins (sea, seb,
sec, sed, see, seg, seh, sei, selj, selk, selm, seln, selo, selp,
selq, and selr), PVL, exfoliatins (A and B) and toxic shock
syndrome toxin 1 (TSST-1) were detected by multiplex
PCRs [23]. MRSA strains were genotyped by analysis of
SmaI macrorestriction fragments of genomic DNA resolved
by PFGE [18]. Patterns were analysed with BioNumerics
software version 2.5 (Applied Maths, Kortrijk, Belgium), as
previously described [24]. Pattern matching was based on
the Dice coefficient for similarity analysis. PFGE profiles
were classified according to previously published criteria
[25]. Groups including patterns differing by six or fewer
DNA fragments were designated by a capital letter (e.g.
A); types including patterns differing by three or fewer
DNA fragments were designated by a numeral (e.g. A20).
PFGE profiles of our CO-MRSA isolates were compared
with a national database of HA-MRSA and CA-MRSA
clones, as previously described [13,18,26]. Determination
of SCCmec type was performed as previously described
[27,28]. Representative isolates from each PFGE type were
tested by multilocus sequence typing (MLST) and assigned
to an ST by use of the MLST database (http://www.
mlst.net).
Hospital environment and staff investigation
As MRSA was recovered from several children with acute
otitis media (AOM) and otorrhoea, we investigated the pos-
sibility of the inanimate environment or healthcare staff in
the ear, nose and throat (ENT) unit being sources of MRSA
contamination. In June 2003, members of the ENT staff
(n = 14) were screened with nasal and inguinal skin swabs,
and environmental swab samples (using agar gel transport
swabs plated within 1 h on Columbia blood agar), were
obtained from microscopes, fibroscopes and other instru-
ments, examination benches, keyboards, and phones.
Statistical analysis
Statistical analysis was performed with Epi Info version 6.
Chi-square tests were used to compare proportions, and a
p-value of < 0.05 was considered to be statistically signifi-
cant.
Results
During the study period, S. aureus was isolated in 1681 dif-
ferent children; in 1392 of these, isolates were first detected
by culture in outpatients or inpatients within 48 h of stay
(CO S. aureus). There were 107 MRSA isolates: 36 were
acquired after 48 h of stay among inpatients, 20 were recov-
ered from children transferred from another hospital, with
surgical wounds or previously colonized, and 51 CO-MRSA
isolates (3.7% of CO S. aureus) were collected from colo-
nized or infected children. No MRSA was detected in the
staff and environment in the otorhinolaryngology unit during
the study period.
CO-MRSA patient characteristics
The 51 children with CO-MRSA had a median age of
24 months (range 0–302 months), and 12 of them (24%)
were aged <3 months. There were 21 (41%) girls, and 33
(65%) children were handled as outpatients.
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Exposure to previously described MRSA infection/coloni-
zation risk factors is presented in Table 1. Among the chil-
dren with CO-MRSA, ten (20%) had no exposure to
healthcare and met the CA-MRSA definition. Among the 12
infants <3 months of age, five had been hospitalized in their
neonatal period and four had parents with a hospitalization
history in the previous year, one being a known MRSA car-
rier.
CO-MRSA clinical presentation and management
The clinical presentation associated with MRSA infections
and colonization is described in Table 2. The majority of the
children (29/51) were only colonized, and 22 children pre-
sented an infection attributable to their CO-MRSA. The age
distribution was different in children presenting with infec-
tion and those presenting with colonization (p 0.034 for het-
erogeneity chi-square) (Fig. 1). Children less than 1 year of
age were more likely to be colonized (88%) than infected,
whereas children from 1 to 12 years of age had more infec-
tions (70%) (p 0.0005). A travel history within the year
before MRSA isolation was more common in infected (11/
22) than in colonized children (6/29) (p 0.03). There were,
however, no differences in the distribution of infection/colo-
nization among children with CA-MRSA and children with
epidemiological risk factors for HA-MRSA.
Eighteen children with CO-MRSA were hospitalized; how-
ever, all of them were only colonized. The 12 infants
<3 months of age were also only colonized. Five outpatients
with cystic fibrosis (CF) were colonized with MRSA and
remained colonized in the following 6-month to 1-year per-
iod. Among the 24 other colonized patients, 11 were decol-
onized with chlorexidine body washes and intranasal
mupirocin therapy for 5 days. Follow-up cultures performed
in nine patients (1 week to 3 months post -treatment) were
negative.
Among the 22 children who presented with a CO-MRSA
infection, none required hospitalization. Seven children with
CO-MRSA infection were initially adequately treated and
were cured. Among the 15 remaining children, three pre-
sented with SSTIs and two with perforated AOM/sinusitis,
which failed to respond to initial therapy with oral amoxycil-
lin–clavulanate or cephalosporin. These five recovered after
treatment was changed to appropriate antibiotics (clindamy-
cin, co-trimoxazole, or ciprofloxacin) or to drainage alone in
one case. Two children presented with chronic suppurative
otitis media, with multiple pathogens recovered from ear
drainage fluid. No response was obtained with various antibi-
otic treatments, and repeated surgery was needed in both
cases.
Strain characteristics
MRSA strains from 37 CO-MRSA patients were further
analysed in the Reference Laboratory. The other 14
patients from whom strains were not available did not
differ in their demographic or clinical characteristics. The
molecular characteristics of the strains are presented
in Table 3 and their antibiotic susceptibility profiles in
TABLE 1. Previous exposure to potential risk factors for
methicillin-resistant Staphylococcus aureus (MRSA) coloniza-
tion/infection among 51 MRSA-colonized/infected children
in Brussels, 2002–2004
Exposure No. of
patients, n = 51












Close contactsa with individuals exposed to MRSA 23b
Chronic disease and/or hospitalization history 14
HCW 10
Nursing home stay 5
MRSA carrier 2
Not recorded (or incomplete) 7
Travel history in the previous year 17
North Africa 5
Europe (France, Spain) 7
Other 5
Not recorded 6
Antibiotic use in the previous 6 months 20
Systemic use 17
Local use only (drops) 3
Not recorded 4
ENT, ear nose and throat; HCW, healthcare worker; NICU, neonatal intensive-
care unit.
aClose contacts: siblings, family, friends or carers with regular contacts (several
times weekly).
bSeveral patients had several at-risk contacts.
TABLE 2. Distribution of colonization and clinical syn-
dromes among 51 community-onset methicillin-resistant





no. (%) (n = 51)
Colonization 29 (56.8)
Benign SSTI infections 8 (15.6)
Abscesses/furuncles 4 (7.8)
Eczema superinfection 4 (7.8)
Perforated AOMa 13 (25.5)
Chronic sinusitis 1 (2.0)
Total infections 22 (43.2)
AOM, acute otitis media; SSTI, skin and soft tissue infection.
aTwo with chronic suppurative otitis.
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Table 4. The 37 strains presented 16 different PFGE pro-
files (Table 3), which were associated with eight different
MLST types. The most common genotypes were ST8-IV
(n = 11), comprising three PFGE types (A20, A22, and
A23), ST5-II (n = 6), with two predominant PFGE types












M F M F M F M F M F M F
12–17 years6–11 years12–59 months4–11 months0–3 months ≥18 years
FIG. 1. Age and sex distribution of children presenting with community-onset methicillin-resistant Staphylococcus aureus infection (n = 22) and
colonization (n = 29), Brussels, 2002–2004. F, female; M, male.
TABLE 3. Molecular typing of community-onset methicillin-resistant Staphylococcus aureus (CO-MRSA) strains and genetic


















1 G10 II 5 TSST-1 sec, sel, egc ant4, ermA 0 C
1 G10 II 5 TSST-1 sed, sel, egc TetM, ant4, ermA 1 C
1 G10 II 5 TSST-1 sec, sel, egc TetM, ant4, ermA 0 C
1 G11 II 5 TSST-1 sec, sel, egc ant4, ermA 0 AOM
1 G11 II 5 TSST-1 sec, sel, egc TetM, ant4, ermA 1 AOM
1 G11 II 5 TSST-1 sec, sel, sek, egc TetM, ant4, ermA 0 C
1 C3 IV 5 TSST-1 sec, sed, sej, sel, ser, egc TetK, ant4, ermC 0 AOM
4 A20 IV 8 – sea ant4, ermA 0 3 C; 1 AOM
1 A20 IV 8 – sea, sed, sej, ser ant4 0 C
5 A22 IV 8 – sea, sed, sej, ser ant4 2 3 C; 2 AOM
1 A23 IV 8 PVL sek, seq TetK 1 Abscess
2 L1 IV 22 – egc – 0 2 C
1 J4 IV 30 PVL sej, sei, sen – 0 Abscess
1 J5 IV CC30c TSST-1 seg, sei, sen ant4 0 C
3 B2 IV 45 – sec, sel, egc ermC 0 3 C
1 B2 IV 45 – sec, seg, sei, sel, sen, seo – 0 C
1 B2 IV 45 – sec, sel, egc – 0 C
1 B2 IV 45 – sec, sel, sek, egc ermC 1 Eczema
3 X1 IV 80 PVL – TetK, aph3 0 1 C; 1 AOM; 1 furuncle
1 X1 IV 80 PVL – TetK, aph3, ermC 1 Eczema
1 Spor1 IV 425 Eta sed ermC 0 C
1 Spor2 IV ND – sea, egc ant4, ermC 1 Impetigo
1 Spor3 IV ND – seh, seh2 TetK, aph3, ermC 0 C
1 Spor4 II ND – sed, sej, seo, ser, egc ant4, ermA 0 AOM
1 NT IV ND – – ant4, ermA 0 AOM
AOM, acute otitis media; C, colonization; CA, community-acquired; Egc, enterotoxin gene cluster locus, encoding five superantigenic enterotoxin genes (seg, sei, sem, sen, and
seo); MLST, multilocus sequence typing; ND, not done; NT, non-typeable; PFGE, pulsed-field gel electrophoresis; PVL, Panton–Valentin leukocidin; SCCmec, staphylococcal
chromosomal cassette mec; TSST-1, toxic shock syndrome toxin 1; –, none of the toxin detected.
Infection type/colonization: Spor1, Spor2, Spor3 and Spor4 represent four different unique PFGE types accounting for less than 1% of the PFGE types used for comparison in
the database.
aMLST determined for one representative strain of each PFGE profile.
bCA-MRSA means CO-MRSA in a child without underlying illness or direct or indirect exposure to hospital or nursing homes.
cStrain belonging to CC30, representing an allelic variant not described in the MLST database. MLST was performed on PVL-positive or TSST-1-positive strains only.
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type (n = 6), and ST80 (n = 4), all from the same PFGE
type (X1).
PVL genes were detected in only six strains from three
different clonal types (ST80-IV (n = 4), ST30-IV, and ST8-IV),
whereas TTST-1 was described in all ST5 strains (ST5-IV and
ST5-II) and in one CC30-IV strain. PVL genes were detected
more frequently in isolates from SSTI (4/6) than was the
TSST-1 gene (0/8) (p 0.001). The one ST8-IV PVL-positive
strain (PFGE type A23) was recovered from a child recently
arrived from Ecuador who had developed a post-varicella
SSTI infection.Only one of eight strains from perforated
AOM carried PVL genes, in a genotype corresponding to
ST80-IV. Among the nine strains from infants <3 months of
age, none carried a toxin gene (PVL, TSST-1, or Eta/b).
The enterotoxin gene patterns showed some diversity
within similar STs and even PFGE types, although some en-
terotoxins or combinations were more likely to be found in
defined clonal types. The enterotoxin SEA gene was found in
all but the PVL-positive ST8-IV strains, alone (n = 4) or asso-
ciated with SED, SEJ and SER toxin genes (n = 6). A com-
plete egc cluster was detected in 14 of 37 (38%) strains,
including all ST5-IV/II TTST-1-positive strains, five of six
ST45-IV strains, and the two ST22-IV strains. Five strains
(14%) had no enterotoxin genes, and four of these belonged
to ST80. Not surprisingly, enteroxin genes were detected in
only two PVL-positive strains, which carried two and three
different genes, respectively, whereas a median of seven dif-
ferent enterotoxin genes was detected in TSST-1-positive
strains (Table 3).
All 37 CO-MRSA strains were susceptible to gentamicin,
linezolid, rifampicin, minocycline, and sulphamethoxazole.
Globally, 46% and 65% of the CO-MRSA strains were sus-
ceptible to erythromycin and clindamycin, respectively. Only
four of 11 ST8-IV isolates were erythromycin-resistant (car-
rying an ermA gene). CA-MRSA strains did not differ from
other CO-MRSA strains in antibiotic resistance resistance
profile. Ciprofloxacin susceptibility was associated with the
presence of the PVL gene (six of six strains as compared
with seven of 30 of the PVL-negative strains) (Fisher exact
test; p 0.0009). Most PVL strains (5/6) were erythromycin-
susceptible and all were clindamycin-susceptible, whereas
TSST-1-positive strains were mostly erythromycin-resistant
(6/8) and clindamycin-resistant (5/8).
Discussion
During a 3-year period, a small proportion of S. aureus
strains recovered in our teaching hospital were CO-MRSA
(3.7%). Moreover, despite our hospital being the largest chil-
dren’s hospital in the country, no CO-MRSA infections
severe enough to require hospitalization were observed dur-
ing the study period. Although these MRSA strains were
acquired before hospital visit/admission, 80% of the children
had previously been in direct or indirect contact with health-
care settings (hospitals, nursing homes, or medical staff).
Many children (38%) also had a travel history, a factor that
has been associated with acquisition of CA-MRSA [4,8,29].
Three different groups of children were colonized or
infected with CO-MRSA. The first group encompassed
infants younger than 3 months of age, who were only colo-
nized. It is well established that healthy neonates have a
higher rate of S. aureus colonization than older children [30].
They acquire the organism from their mother, or from their
environment, including the hospital nursery and staff [31–33].
In our study, MRSA strains recovered from these infants
belonged to healthcare-associated strain types, suggesting
that transmission occurred in the maternity wards or in the
neonatal intensive-care unit. CF patients constitute a second
group of S. aureus-colonization prone people [34]. In some
settings, they have often been found to be colonized with
healthcare-associated MRSA strains [34,35]. Recently, CF
patients were also shown to be commonly colonized with
CA-MRSA in Texas, a region where CA-MRSA is prevalent
in the paediatric population [36]. In the present study, MRSA
strains from diverse genetic backgrounds (including one
TABLE 4. Antibiotic susceptibility profile of community-onset methicillin-resistant Staphylococcus aureus determined by disk
diffusion according to toxin type, Brussels, 2002–2004
Toxin type
No. of strains susceptible to antibiotic
Oxa Gen Tob Kan Ery Clin Lz Rif Fus Mup Tet Min Cip SXT
PVL (n = 6) 0 6 6 2 5 6 6 6 2 6 1 6 6 6
TSST-1 (n = 8) 0 8 0 1 2 3 8 8 7 8 1 8 3 8
Other (n = 23) 2a 23 10 9 10 15 23 23 23 19 20 23 4 23
Total (%) (n = 37) 2 (0.5) 37 (100) 16 (43) 12 (32) 17 (46) 24 (65) 37 (100) 37 (100) 32 (86) 33 (89) 22 (59) 37 (100) 13 (35) 37 (100)
Oxa, oxacillin; Gen, gentamicin; Tob, tobramycin; Kan, kanamycin; Ery, erythromycin; Clin, clindamycin; Lz, linezolid; Rif, rifampicin; Fus, fusidic acid; Mup, mupirocin; Tet, tet-
racycline; Min, minocycline; Cip, ciprofloxacin; SXT, sulphamethoxazole–trimethoprim; PVL, Panton–Valentin leukocidin; TSST-1, toxic shock syndrome toxin 1.
aTwo strains that tested resistant with Vitek II expressed a susceptible phenotype with disk diffusion.
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ST80-IV PVL-positive strain) were recovered from five CF
outpatients. A third group comprises patients with chronic
ENT conditions, such as chronic suppurative otitis or sinusi-
tis, who are also more likely to become colonized/infected
with MRSA [37,38]. In our patient group, the most common
MRSA infection was perforated AOM, and 89% of these
cases were caused by common hospital MRSA types. Few
reports of draining AOM with MRSA are available in the lit-
erature. In a recent report, Brook found an increase in
MRSA infection among children with perforated AOM in the
period after PCV7 introduction as compared with the pre-
vaccine period [37].
As already reported in previous studies [3,39], we found
the distinction between HA-MRSA and CA-MRSA to be arti-
ficial among CO-MRSA strains. In our setting, CO-MRSA
strains were often HA-MRSA type strains, as 22 of 37 (60%)
of the strains belonged to the major Belgian hospital MRSA
clones (ST8-IV PVL-negative strains, ST5-II/IV, ST45-IV, and
ST22-IV). The one ST8-IV PVL-positive strain (PFGE
type A23) was probably not a USA300 typical clone, as it
was negative for the ArcA gene by PCR (result not shown).
All of the other ST8-IV isolates were distributed in two dis-
tinct PFGE types (A20 and A22) both commonly found in
isolates from Belgian hospitals and similar to the Lyon clone
widespread in French hospitals [40]. In our paediatric popula-
tion, 22% of CO-MRSA strains carried the TSST-1 gene, as
compared with 0.9% in hospital MRSA strains from the global
population in Belgium [41]. Nevertheless, most TSST-1-posi-
tive strains belonged to the same genotype, ST5-II; this is
closely related to the ‘New York–Japan clone’, which has
been associated with neonatal toxic shock syndrome (TSS)-
like exanthematous disease in Japanese hospitals and with
TSS in Belgium [42,43]. TSST-1-positive MRSA strains
belonging to ST5, sharing common features with the ‘New
York–Japan clone’, have also been reported in the French
paediatric population, where they have been associated with
a variety of infections (including TSS) and both nosocomial
and community acquisition [44].
In our study, we found a low frequency of isolates with
all of the molecular characteristics of the typical CA-MRSA
clones (six isolates). In particular, a low frequency of isolates
carrying PVL was found. The analysis of molecular data sug-
gests that the great majority of the isolates were of hospital
origin. In fact, even the strains collected from children with
no healthcare contact were related to isolates traditionally
found in Belgian hospitals.A recent carriage study conducted
in the same Belgian region identified a 3% rate of MRSA
nasopharyngeal colonization among healthy preschool chil-
dren. Half of these strains belonged to CC8, spa type t-008,
corresponding to one of the major Belgian hospital clones,
A-ST8-SCCmecIV. Moreover, most isolates were multiresis-
tant to antibiotics, and none of these MRSA strains was
PVL-positive (Blumental et al., 28th ESPID, Nice, France,
2010).
CO-MRSA strains from our paediatric population showed
marked clonal heterogeneity, as was also reported in other
studies performed in Europe among the global population
[5,12–14]. This contrasts sharply with the situation in the
USA, where the USA300 clone (ST8-IV) has reached epi-
demic proportions, in both children and adults [45].
In conclusion, CO-MRSA remains uncommon in our pae-
diatric population. So far, there is no need to modify the
empirical treatment of suspected S. aureus infections, except
in cases of severe SSTI or life-threatening necrotizing pneu-
monia. However, continuous monitoring of the MRSA rate is
needed for inpatients and outpatients, specifically in children
with perforated or refractory AOM, neonates, and special
populations with chronic diseases. Toxin detection and
molecular typing should be performed in cases of MRSA
recovered from SSTIs.
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